With the success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture. Upstream manufacturing processes for recombinant adeno-associated virus (AAV) and lentivirus (LV) are largely dependent on transient transfection of multiple plasmid DNA constructs encoding essential viral proteins. To produce the virus needed for these therapies, processes must be adapted to bioreactor scale for cGMP production. In response to this need, Mirus Bio has established solutions including a novel transfection reagent that increases AAV and LV titers 2-10-fold over existing technologies, and a unique enhancer that increases titer over the reagent up to 4X.
This webinar adopts a roundtable format with a panel comprising end users as well as a Mirus Bio senior research scientist.
Watch this webinar to:
Director of Upstream Process Development, MeiraGTx
Florian holds a B.Eng degree in chemical engineering from Polytechnique Montreal and a Doctorate in Pharmacy from University of Lyon. He has 9 years of experience in Upstream Process Development and worked on optimizing several process modalities, ranging from E.Coli fermentation for antibody fragment production to adherent and suspension mammalian cell culture for AAV manufacturing. Currently, he is the Director of Upstream Process Development at MeiraGTx, where he spent the last 6 years developing and optimizing AAV manufacturing platforms based on suspension HEK293 cells and transient transfection.
René Gantier is the Senior Director R&D, Advanced Bioprocess Applications at Repligen. He has more than 20 years of experience developing production and purification processes for biotherapies. René holds a MSc in Cell Biology from the University of Nantes (France) and a PhD in Biochemistry from the University of Rouen (France). He started his career in the biotechnology industry as a scientist developing long-lasting therapeutic cytokines at Nautilus Biotech (France), before joining Pall Life Sciences as a downstream processing field application specialist, and then expanded his role to lead the Biotech Process R&D team developing end-to-end upstream-downstream continuous bioprocessing solutions for mAbs and cell/gene therapies. In his current role at Repligen, he leads the development of advanced bioprocess applications and technologies with a focus on next generation cell and gene therapy manufacturing processes.